Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Eunice S Wang, Aaron D Goldberg, Martin Tallman, Roland B Walter, Chatchada Karanes, Karamjeet Sandhu, Carlos E Vigil, Robert Collins, Vinay Jain, Richard M Stone
PURPOSE: Crenolanib is a second-generation tyrosine kinase inhibitor with activity against FLT3-ITD - and TKD -mutant AML. We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3 -mutant AML. METHODS: Eligible patients were 18 years and older. Induction chemotherapy consisted of cytarabine (100 mg/m2 ) continuous infusion on days 1-7 and anthracycline (daunorubicin 60-90 mg/m2 or idarubicin 12 mg/m2 , once daily) on days 1-3 followed by consolidation with high-dose cytarabine (1-3 g/m2 twice daily on days 1, 3, 5) and/or allogeneic transplant...
February 7, 2024: Journal of Clinical Oncology
#2
JOURNAL ARTICLE
Jae H Park, Sean Devlin, Benjamin H Durham, Eric S Winer, Scott Huntington, Gottfried von Keudell, Shreya Vemuri, Madhulika Shukla, Victoria Falco, Bernadette Cuello, Steven Gore, Richard Stone, Omar Abdel-Wahab, Martin S Tallman
Vemurafenib and Obinutuzumab for Hairy Cell LeukemiaIn this study of vemurafenib plus obinutuzumab of patients with previously untreated hairy cell leukemia, treatment was administered for four cycles, and the primary end point was complete remission rate. Twenty-seven of 30 patients completed all four cycles of treatment and achieved complete remission. No dose-limiting toxicity was observed.
October 2023: NEJM Evid
#3
JOURNAL ARTICLE
Martin S Tallman
No abstract text is available yet for this article.
February 1, 2024: Haematologica
#4
JOURNAL ARTICLE
B Bishal Paudel, Su-Fern Tan, Todd E Fox, Johnson Ung, Upendarrao Golla, Jeremy J P Shaw, Wendy Dunton, Irene S Lee, Wisam Fares, Satyam Patel, Arati Sharma, Aaron D Viny, Brian M Barth, Martin S Tallman, Myles C Cabot, Francine E Garrett-Bakelman, Ross L Levine, Mark Kester, David J Feith, David F Claxton, Kevin A Janes, Thomas P Loughran
No abstract text is available yet for this article.
January 3, 2024: Blood Advances
#5
JOURNAL ARTICLE
Oluwatobi Odetola, Martin S Tallman
Acute promyelocytic leukemia (APL), a phenotypically and genotypically unique subtype of acute myeloid leukemia, has seen unprecedented advances in its management since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide. However, the phenomenal pharmacologic conversion of this once highly fatal disease to one with a long-term survival exceeding 90% among patients who survive induction remains impaired by the significant incidence of early death (ED) reaching 30% in some real-world studies...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
#6
JOURNAL ARTICLE
Ryan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S Bowman, JinJuan Yao, Jacklyn Casanova, Yun-Te David Lin, Kseniya Petrova-Drus, Abhinita S Mohanty, Ruben Bacares, Jamal Benhamida, Satshil Rana, Anna Razumova, Chad Vanderbilt, Anoop Balakrishnan Rema, Ivelise Rijo, Julie Son-Garcia, Ino de Bruijn, Menglei Zhu, Sean Lachhander, Wei Wang, Mohammad S Haque, Venkatraman E Seshan, Jiajing Wang, Ying Liu, Khedoudja Nafa, Laetitia Borsu, Yanming Zhang, Umut Aypar, Sarah P Suehnholz, Debyani Chakravarty, Jae H Park, Omar Abdel-Wahab, Anthony R Mato, Wenbin Xiao, Mikhail Roshal, Mariko Yabe, Connie Lee Batlevi, Sergio Giralt, Gilles Salles, Raajit Rampal, Martin Tallman, Eytan M Stein, Anas Younes, Ross L Levine, Miguel-Angel Perales, Marcel R M van den Brink, Ahmet Dogan, Marc Ladanyi, Michael F Berger, A Rose Brannon, Ryma Benayed, Ahmet Zehir, Maria E Arcila
Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor only sequencing assays are limited in their ability to identify definitive somatic variants, which can lead to ambiguity in clinical reporting and patient management. Here, we describe the MSK-IMPACT Heme cohort, a comprehensive data set of somatic alterations from paired tumor and normal DNA using a hybridization capture-based next generation sequencing platform...
October 28, 2023: Nature Communications
#7
JOURNAL ARTICLE
Despoina Papazoglou, Victoria Wang, Tait D Shanafelt, Connie Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S Tallman, Neil E Kay, Alan G Ramsay
Bruton's tyrosine kinase Inhibitors (BTKis) that target B cell receptor signaling have led to a paradigm shift in CLL treatment. BTKis have been shown to reduce abnormally high CLL-associated T cell counts and the expression of immune checkpoint receptors concomitantly with tumor reduction. However, the impact of BTKi therapy on T cell function has not been fully characterized. Here, we performed longitudinal immunophenotypic and functional analysis of pre- and on-treatment (6- and 12-months) peripheral blood samples from patients in the phase 3 E1912 trial comparing ibrutinib-rituximab to fludarabine, cyclophosphamide and rituximab (FCR)...
October 12, 2023: Blood
#8
JOURNAL ARTICLE
Seemal R Desai, Linda Stein Gold, Michael C Cameron, Alexandra Golant, G Michael Lewitt, Matthew J Bruno, George Martin, Philip M Brown, David S Rubenstein, Victoria Butners, Anna M Tallman
Tapinarof cream 1% (VTAMA® ; Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl hydrocarbon receptor agonist approved by the US Food and Drug Administration (FDA) to treat plaque psoriasis in adults and under investigation for the treatment of psoriasis in children down to 2 years of age, and for atopic dermatitis in adults and children down to 2 years of age. The PSOARING phase 3 clinical trial program evaluated tapinarof cream 1% once daily (QD) in adults with mild to severe plaque psoriasis for up to 52 weeks (NCT03956355, NCT03983980, NCT04053387)...
September 11, 2023: Dermatology and Therapy
#9
JOURNAL ARTICLE
Karthik Nath, Jasme Lee, Theresa A Elko, Lauren Levy, Elaina Preston, Sean M Devlin, Doris M Ponce, Richard J Lin, Brian C Shaffer, Christina Cho, Ioannis Politikos, Ann A Jakubowski, Jae H Park, Raajit Rampal, Miguel-Angel Perales, Martin S Tallman, Juliet N Barker, Ellin Berman, Roni Tamari, Eytan Stein, Sergio A Giralt, Boglarka Gyurkocza
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate and eligible for HCT did not subsequently undergo transplant. Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy...
September 9, 2023: American Journal of Hematology
#10
REVIEW
Susan DeWolf, Martin S Tallman, Jacob M Rowe, Meira Yisraeli Salman
Although allogeneic hematopoietic cell transplantation (allo-HCT) remains the backbone of curative treatment for the majority of fit adults diagnosed with AML, there is indeed a subset of patients for whom long-term remission may be achieved without transplantation. Remarkable changes in our knowledge of AML biology in recent years has transformed the landscape of diagnosis, management, and treatment of AML. Specifically, markedly increased understanding of molecular characteristics of AML, the expanded application of minimal/measurable residual diseases testing, and an increased armamentarium of leukemia-directed therapeutic agents have created a new paradigm for the medical care of patients with AML...
October 10, 2023: Journal of Clinical Oncology
#11
Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T Gildea, Samuel Haddox, Tak Lee, H Moses Murdock, Caroline Sheridan, Alexis Thurmond, Ling Wang, Martin Carroll, Larry D Cripe, Hugo Fernandez, Christopher E Mason, Elisabeth Paietta, Gail J Roboz, Zhuoxin Sun, Martin S Tallman, Yanming Zhang, Mithat Gönen, Ross Levine, Ari M Melnick, Maria Kleppe, Francine E Garrett-Bakelman
No abstract text is available yet for this article.
July 6, 2023: Blood Cancer Journal
#12
JOURNAL ARTICLE
Sara Zarnegar-Lumley, Todd Alonzo, Robert B Gerbing, Megan Othus, Zhuoxin Sun, Rhonda E Ries, Jim Wang, Amanda R Leonti, Matthew A Kutny, Fabiana Ostronoff, Jerald P Radich, Frederick R Appelbaum, Era L Pogosova-Agadjanyan, Kristen M O'Dwyer, Martin S Tallman, Mark R Litzow, Ehab Atallah, Todd M Cooper, Richard Aplenc, Omar I Abdel-Wahab, Alan S Gamis, Selina M Luger, Harry P Erba, Ross L Levine, E Anders Kolb, Derek L Stirewalt, Soheil Meshinchi, Katherine Tarlock
Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the prevalence, co-occurring mutational profile, and prognostic significance of IDH mutations in AML across the age spectrum. Our cohort included 3,141 patients aged <1 month-88 years treated on CCG/COG (N=1872), SWOG (N=359), ECOG (N=397) trials and in Beat AML (N=333) and TCGA (N=180) genomic characterization cohorts...
June 2, 2023: Blood Advances
#13
JOURNAL ARTICLE
James M Foran, Zhuoxin Sun, Catherine Lai, Hugo F Fernandez, Larry D Cripe, Rhett P Ketterling, Janis Racevskis, Selina M Luger, Elisabeth Paietta, Hillard M Lazarus, Yanming Zhang, John M Bennett, Ross L Levine, Jacob M Rowe, Mark R Litzow, Martin S Tallman
BACKGROUND: Obesity (body mass index [BMI] ≥30 kg/m2 ) is an important epidemiological risk factor for developing acute myeloid leukemia (AML). Therefore, the authors studied the association of obesity with clinical and genetic phenotype and its impact on outcome in adults with AML. METHODS: The authors analyzed BMI in 1088 adults who were receiving intensive remission induction and consolidation therapy in two prospective, randomized therapeutic clinical trials of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network: E1900 (ClinicalTrials...
April 25, 2023: Cancer
#14
JOURNAL ARTICLE
Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, Noushin Farnoud, Abhinita S Mohanty, Zoe S Stone-Molloy, Jordan Chervin, Brian J Ball, Zachary D Epstein-Peterson, Maria E Arcila, Aaron J Stonestrom, Andrew Dunbar, Sheng F Cai, Jacob L Glass, Mark B Geyer, Raajit K Rampal, Ellin Berman, Omar I Abdel-Wahab, Eytan M Stein, Martin S Tallman, Ross L Levine, Aaron D Goldberg, Elli Papaemmanuil, Yanming Zhang, Mikhail Roshal, Andriy Derkach, Wenbin Xiao
Accurate classification and risk stratification is critical for clinical decision making in AML patients. In the newly proposed World Health Organization (WHO) and International Consensus classifications (ICC) of hematolymphoid neoplasms, the presence of myelodysplasia-related (MR) gene mutations is included as one of the diagnostic criteria of AML, myelodysplasia-related (AML-MR), largely based on the assumption that these mutations are specific for AML with an antecedent myelodysplastic syndrome. ICC also prioritizes MR gene mutations over ontogeny (as defined by clinical history)...
May 4, 2023: Blood Advances
#15
B Bishal Paudel, Su-Fern Tan, Todd E Fox, Johnson Ung, Jeremy Shaw, Wendy Dunton, Irene Lee, Arati Sharma, Aaron D Viny, Brian M Barth, Martin S Tallman, Myles Cabot, Francine E Garrett-Bakelman, Ross L Levine, Mark Kester, David Claxton, David J Feith, Kevin A Janes, Thomas P Loughran
UNLABELLED: Acute myeloid leukemia (AML) is an aggressive disease with complex and heterogeneous biology. Although several genomic classifications have been proposed, there is a growing interest in going beyond genomics to stratify AML. In this study, we profile the sphingolipid family of bioactive molecules in 213 primary AML samples and 30 common human AML cell lines. Using an integrative approach, we identify two distinct sphingolipid subtypes in AML characterized by a reciprocal abundance of hexosylceramide (Hex) and sphingomyelin (SM) species...
April 17, 2023: bioRxiv
#16
JOURNAL ARTICLE
Umeshkumar Vekariya, Monika Maria Toma, Margaret Nieborowska-Skorska, Bac Viet Le, Marie-Christine Caron, Anna-Mariya Kukuyan, Katherine Sullivan-Reed, Paulina Podszywalow-Bartnicka, Kumaraswamy Naidu Chitrala, Jessica Atkins, Malgorzata Drzewiecka, Wanjuan Feng, Joe Chan, Srinivas Chatla, Konstantin Golovine, Jaroslav Jelinek, Tomasz Sliwinski, Jayashri Ghosh, Ksenia Matlawska-Wasowska, Gurushankar Chandramouly, Reza Nejati, Mariusz A Wasik, Stephen Sykes, Katarzyna Piwocka, Emir Hadzijusufovic, Peter Valent, Richard T Pomerantz, George Morton, Wayne Childers, Huaqing Zhao, Elisabeth Paietta, Ross L Levine, Martin S Tallman, Hugo Fernandez, Mark R Litzow, Gaorav Gupta, Jean-Yves Masson, Tomasz Skorski
Leukemia cells accumulate DNA damage but altered DNA repair mechanisms protect them from apoptosis. We showed here that formaldehyde generated by serine/one-carbon cycle metabolism contributed to accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells, especially in driver clones harboring oncogenic tyrosine kinases [OTKs: FLT3(ITD), JAK2(V617F), BCR/ABL1]. To counteract this effect, OTKs enhanced the expression of DNA polymerase theta (POLq) by ERK1/2 serine/threonine kinase-dependent inhibition of c-CBL E3 ligase-mediated ubiquitination of POLq and its proteasomal degradation...
December 29, 2022: Blood
#17
REVIEW
Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A Rogers, Alan Saven, John F Seymour, Tamar Tadmor, Martin S Tallman, Constantine S Tam, Philip A Thompson, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever
A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission...
December 13, 2022: Blood Cancer Journal
#18
JOURNAL ARTICLE
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K Rampal, Marcos de Lima, James Foran, Amir T Fathi, Aric Cameron Hall, Meagan A Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M Stone, Stephen Strickland, Matthew J Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P Aung, Branko Cuglievan, Yazan Madanat, Mohamed A Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A Lane
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible...
February 9, 2023: Blood
#19
JOURNAL ARTICLE
Chezi Ganzel, Zhuoxin Sun, Timour Baslan, Yanming Zhang, Mithat Gönen, Omar I Abdel-Wahab, Janis Racevskis, Francine Garrett-Bakelman, Scott W Lowe, Hugo F Fernandez, Rhett Ketterling, Selina M Luger, Mark Litzow, Hillard M Lazarus, Jacob M Rowe, Martin S Tallman, Ross L Levine, Elisabeth Paietta
Measurable residual disease (MRD) assessment provides a potent indicator of the efficacy of anti-leukemic therapy. It is unknown, however, whether integrating MRD with molecular profiling better identifies patients at risk of relapse. To investigate the clinical relevance of MRD in relation to a molecular-based prognostic schema, we measured MRD by flow cytometry in 189 AML patients enrolled in ECOG-ACRIN E1900 trial (NCT00049517) in morphologic complete remission (CR) (28.8 % of the original cohort) representing 44...
December 2022: Leukemia Research
#20
JOURNAL ARTICLE
Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David Claxton, Matthew C Foster, Frederick R Appelbaum, Harry P Erba, Mark R Litzow, Martin S Tallman, Richard M Stone, Richard A Larson, Anjali S Advani, Wendy Stock, Selina M Luger
Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However, similar correlation in adults is lacking. Here, we studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated on the US intergroup CALGB 10403 study and examined the prognostic impact of early discontinuation (ED) (defined as <4 of 5 or 6 planned doses) on survival outcomes...
October 21, 2022: Blood Advances
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
